Analysts Change Ratings on These Healthcare Stocks in Mid-December

Stock analysts reiterated ratings in the Healthcare sector for the week ending December 16th, 2011 for the following companies:

Genomic Health (NASDAQ:GHDX): Ladenburg Thalmann reiterated its rating of Buy for this company and changed its price target from $26 to $32 on Dec 12th. The shares recently traded at $26.14, down $1.4, or 5.08% since the analyst’s rating. About the company: Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer. The Company’s diagnostic services provide information on the likelihood of disease recurrence and response to certain types of therapy. Get the most recent company news and stock data here >>

ViroPharma (NASDAQ:VPHM): Oppenheimer reiterated its rating of Outperform for this company and changed its price target from $23 to $32 on Dec 15th. The shares recently traded at $27.21, down $0.59, or 2.12% since the analyst’s rating. About the company: ViroPharma Incorporated is a biopharmaceutical company committed to the commercialization, development, and discovery of new medicines. The Company’s products include a treatment for prophylaxis of hereditary angioedema as well a capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (NYSE:CDI) and enterocolitis. Get the most recent company news and stock data here >>

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet